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m icroRNAs (miRNAs) are a class of
small regulatory RNAs that regu-
late gene expression at the post-transcrip-
tional level. miRNAs play important roles
in the regulation of development, growth,
and metastasis of cancer, and in deter-
mining the response of tumor cells to
anticancer therapy. In recent years, they
have also emerged as important regulators
of autophagy, a lysosomal-mediated path-
way that contributes to degradation of
a cell’s own components. Imatinib, a
targeted competitive inhibitor of the
BCR-ABL1 tyrosine kinase, has revolu-
tionized the clinical treatment of chronic
myelogenous leukemia (CML). We
demonstrate that MIR30A-mediated
autophagy enhances imatinib resistance
against CML including primary stem
and progenitor cells. MIR30A, but not
MIR101, is a potent inhibitor of auto-
phagy by selectively downregulating
BECN1 and ATG5 expression in CML
cells. MIR30A mimics, as well as knock-
down of BECN1 and ATG5, increases
intrinsic apoptotic pathways. In contrast,
the antagomir-30A increases autophagy
and inhibits intrinsic apoptotic pathways,
confirming that autophagy serves to pro-
tect against apoptosis. Taken together,
these data clarify some of the underlying
molecular mechanisms of tyrosine kinase
inhibitor-induced autophagy.
Autophagy is an evolutionarily conserved
mechanism for degradation of cytoplasmic
components including organelles and pro-
teins, regulated primarily by autophagy-
related (ATG) genes. Physiological and
pathophysiological roles of autophagy have
been linked with cellular homeostasis and
a number of human diseases including
cancer. Most cancer treatments induce
autophagy in the remaining, resistant
cancer cells, with inhibition of autophagy
promoting sensitivity to therapy. The
mode of activation of autophagy and its
potential protective role remain incom-
pletely understood. Our recent study
indicates that MIR30A specifically regu-
lates ATG protein expression during
CML therapy, and that levels of miRNAs
directly control the activity of autophagy
and effectiveness of chemotherapy
(Fig.1). Thus miRNAs may represent an
attractive therapeutic target, and warrant
further development of agents to target
MIR30A-mediated autophagy, which
could have a significant therapeutic impact
on CML.
MIR30A selectively regulates ATG
gene expression in CML cells. In CML,
BCR-ABL1 tyrosine kinase appears acti-
vated, resulting in excessive proliferation of
white blood cells. Imatinib binds directly
to the ATP binding pocket within the
kinase, preventing its activity, and thereby
causing tumor cell death. Emergence of
resistance to imatinib has become a
significant clinical problem. Recent studies
indicate autophagy regulates imatinib
resistance in CML cells including the
CML stem cells. Moreover, work on
miRNAs has helped us to understand the
mechanism of dysfunction of autophagy in
normal and tumor cells. There is a great
deal of interest in investigating whether
and how miRNAs regulates effectiveness
of imatinib therapy in CML cells. We
demonstrate that MIR30A, but not
other miRNAs such as MIR101,i s
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dose-dependently downregulated in K562
and primary CML cells. Moreover, imati-
nib induces protein and mRNA expression
of BECN1 and ATG5, but not other ATGs
such as ULK1 and ATG7 in K562 and
primary CML cells. Importantly, down-
regulation of MIR30A expression by
antagomir-30A promotes mRNA and pro-
tein expression of BECN1 and ATG5 in
K562 cells with or without imatinib
treatment. Conversely, upregulation of
MIR30A expression by MIR30 mimics
inhibits both mRNA and protein expres-
sion of BECN1 and ATG5, but not ULK1
and ATG7 in CML cells. Individual
mRNAs may also be targeted by other
miRNAs in various cell types. Thus global
miRNA expression profiling and evalu-
ation of MIR30A target genes using
microarray technology is required in future
studies.
MIR30A regulates autophagy in CML
cells. BECN1 and ATG5 have been
previously characterized as key ATGs to
regulate sequential steps in the autophagy
process, although BECN1-independent
and ATG5-independent autophagic path-
ways exist. MIR30A negatively regulates
BECN1 as well as ATG5 expression, and
thus we propose that MIR30A is a
potential inhibitor of autophagy. To
address this hypothesis, we used a
MIR30 mimic and antagomir-30A to
modulate cellular levels of MIR30A in
K562 cells and analyzed autophagy using
three different strategies. The formation of
the autophagosome was monitored by
endogenous microtubule-associated pro-
tein 1 light chain 3 (LC3) aggregation
revealed by staining with a specific LC3
antibody. The protein level of LC3 was
determined by western blotting with or
without combination of the lysosomal
protease inhibitors E64d and pepstatin A.
The ultrastructure of autophagic vesicles
Figure1. MIR30A-mediated autophagy promotes imatinib resistance in CML cells. Imatinib, a member of the BCR-ABL1 tyrosine kinase inhibitors, inhibits
MIR30A levels by unknown mechanisms. MIR30A selectively regulates ATG protein expression in CML cells. After transcription, MIR30A binds to cis-
regulatory sites, usually in the 3’ UTR of the mRNA, and represses protein translation of BECN1, ATG5 and other unknown ATG genes. BECN1 and ATG5 are
required for nucleation and elongation, respectively, of double-membraned phagophores to form vesicles named autophagosomes (also called
autophagic vacuoles). Upregulated autophagy promotes survival of CML primary stem and progenitor cells, which are usually resistant to imatinib.
TF, transcription factor.
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was assessed by transmission electron
microscopy. We demonstrated that
treatment with MIR30 mimic inhibits
imatinib-induced expression of LC3-II,
formation of LC3 puncta and autophagic
vesicles. In contrast, treatment with antag-
omir-30A increases imatinib-induced
autophagic flux. These findings suggest
that MIR30A is a negative regulator of
imatinib-induced autophagy in CML cells.
Interestingly, MIR30A has no effects on
rapamycin-induced expression of LC3-II,
suggesting that MIR30A regulates auto-
phagy in an MTOR-independent manner.
MIR30A-mediated autophagy limits
the effectiveness of BCR-ABL1 tyrosine
kinase inhibitors. BCR-ABL1 tyrosine
kinase inhibitors (TKIs) treatment induces
autophagy, and inhibition of autophagy
enhances the effect of TKIs on CML cells.
MIR30A mimics significantly decrease cell
viability and enhance imatinib as well as
other TKIs (e.g., nilotinib and dasatinib)
induce apoptosis in CML cells, suggesting a
wide role for MIR30A in regulating the
effectiveness of TKIs. In contrast, antag-
omir-30A increases autophagy and decreases
apoptosis in K562 and primary CML cells
after treatment with these TKIs. Similar
with other studies, knockdown of BECN1
and ATG5 by specific shRNA transfection
increases apoptosis in K562 cells following
imatinibtreatment. Notably,knockdownof
BECN1 andATG5 restoresthesensitivity to
imatinib-induced apoptosis following treat-
ment with antagomir-30A, suggesting that
BECN1 and ATG5 are downstream target
genes in antagomir-30A-mediated drug
resistance.
MIR30A-mediates autophagy and limits
intrinsic apoptosis. Imatinib induces
mitochondria-dependent intrinsic apopto-
sis of CML cells, but how the drug
promotes this process is only partially
understood. There is an extremely com-
plex relationship between autophagy and
apoptosis because they share common
stimuli, cellular signaling mechanisms,
and regulators. We demonstrated that
MIR30A mimics, as well as knockdown
of BECN1 and ATG5, increases imatinib-
induced intrinsic apoptotic events such as
loss of mitochondrial membrane potential
(DYm), increased BAX mitochondrial
translocation, increased cytochrome c
release and activation of CASP9.
Moreover, knockdown of BECN1 and
ATG5 increases imatinib-induced loss
of DYm and activation of CASP9 in
antagomir-30A-transfected K562 cells.
These findings suggest that MIR30A-
mediated expression of BECN1 and
ATG5 is required for imatinib-induced
resistance to mitochondria-dependent
intrinsic apoptosis. It is unclear whether
MIR30A regulates mitochondrial auto-
phagy, namely mitophagy, which has
long been proposed to remove damaged
and dysfunctional mitochondria, and
control mitochondrial quality.
Effects of MIR30A-mediated auto-
phagy on drug resistance in CML stem
cells. CML is a stem cell disease, and any
curative therapy must eradicate the stem
cell, which is usually resistant to imatinib.
Previous studies have shown that TKIs in
combination with inhibition of autophagy
results in near complete eradication of
CML stem cells. We find that the
expression of MIR30A is lower in CML
CD34
+ stem and progenitor cells com-
pared with CD34
- cells. Decrease of
MIR30A is observed following imatinib
treatment in CD34
+ cells. As expected, the
level of BECN1 is increased in CD34
+
cells with or without imatinib treatment,
suggesting that autophagy is upregulated
in CML stem cells. Inhibition of BECN1
or treatment with a MIR30A mimic
restores sensitivity of CML stem cells to
imatinib. Thus, targeting MIR30A-
mediated autophagy is a novel anticancer
strategy with therapeutic implications for
imatinib resistance in patients with CML
targeting the primary stem/progenitor
cells. Additional work is necessary to
explore the molecular characterization of
MIR30A-mediated autophagy and
the upstream mechanism regarding how
imatinib regulates MIR30A expression.
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